SGLT2 Inhibitors for Heart Attack Recovery
This study is testing if a medication called SGLT2 inhibitor can help your heart recover and reduce its enlargement after a heart attack. You may be able to join if you've had your first heart attack, had a procedure to open blocked arteries (primary PCI), and have some heart muscle weakness. The study will look at changes in the size of your heart's pumping chambers (LVESVI and LVEDVI) after six months. We are looking for 81 participants, but the current recruitment status is unclear.
- Study design
- This study is an interventional trial, meaning participants will receive either the SGLT2 inhibitor or a placebo. It aims to enroll 81 participants.
- What's involved
- You would take a pill once daily for six months, have a cardiac MRI during your initial hospitalization, receive follow-up phone calls at 1 and 3 months, and have another cardiac MRI and clinic visit at six months.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for six months, with primary endpoints measured at that time.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Jay Traverse, MD · PRINCIPAL_INVESTIGATOR · Minneapolis Heart Institute Foundation
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Change in LVESVI6 Months
Change in LVESVI at 6 months as measured by MRI.
- Change in LVEDVI6 Months
Change in LVEDVI at 6 months as measured by MRI.